药明康德(603259.SH)全资子企业拟认购1000万欧元投资基金份额

智通财经11-15

智通财经APP讯，药明康德(603259.SH)公告，2024年11月15日，公司全资子企业WuXi PharmaTech Healthcare Fund I L.P.(简称“WuXi Fund I”)与 Sofinnova Capital XI GP S.à r.l.(简称“普通合伙人”)签署 Subscription Agreement(简称“认购协议”)，约定由 WuXi Fund I 认缴 Sofinnova Capital XI SCSp SICAV-RAIF(简称“投资基金”)1000万欧元的投资基金份额(简称“本次投资”)，约占已募集投资基金份额的4.40% (WuXi Fund I 所持投资基金份额比例将随投资基金后续募集金额增加而进一步稀释)。截至本公告日，WuXi Fund I尚未支付投资款，后续WuXi Fund I将以自有资金根据认购协议的要求履行投资款的支付义务。

据悉，投资基金依据卢森堡大公国法律组建，专注于在世界范围内投资生命科学领域(特别是生物医药及医疗器械行业)的初创企业。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483334901?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-15 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483334901","market":"hk","top_or_hot":-1,"title":"药明康德(603259.SH)全资子企业拟认购1000万欧元投资基金份额","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(603259.SH)公告，2024年11月15日，公司全资子企业WuXi PharmaTech Healthcare Fund I L.P.(简称“WuXi Fund I”)与 Sofinnova Capital XI GP S.à r.l.(简称“普通合伙人”)签署 Subscription Agreement(简称“认购协议”)，约定由 WuXi Fund I 认缴 Sofinnova Capital XI SCSp SICAV-RAIF(简称“投资基金”)1000万欧元的投资基金份额(简称“本次投资”)，约占已募集投资基金份额的4.40% (WuXi Fund I 所持投资基金份额比例将随投资基金后续募集金额增加而进一步稀释)。截至本公告日，WuXi Fund I尚未支付投资款，后续WuXi Fund I将以自有资金根据认购协议的要求履行投资款的支付义务。</p><p>据悉，投资基金依据卢森堡大公国法律组建，专注于在世界范围内投资生命科学领域(特别是生物医药及医疗器械行业)的初创企业。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德(603259.SH)全资子企业拟认购1000万欧元投资基金份额</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德(603259.SH)全资子企业拟认购1000万欧元投资基金份额\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2024-11-15 17:08</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/603259\">药明康德</a>(603259.SH)公告，2024年11月15日，公司全资子企业WuXi PharmaTech Healthcare Fund I L.P.(简称“WuXi Fund I”)与 Sofinnova Capital XI GP S.à r.l.(简称“普通合伙人”)签署 Subscription Agreement(简称“认购协议”)，约定由 WuXi Fund I 认缴 Sofinnova Capital XI SCSp SICAV-RAIF(简称“投资基金”)1000万欧元的投资基金份额(简称“本次投资”)，约占已募集投资基金份额的4.40% (WuXi Fund I 所持投资基金份额比例将随投资基金后续募集金额增加而进一步稀释)。截至本公告日，WuXi Fund I尚未支付投资款，后续WuXi Fund I将以自有资金根据认购协议的要求履行投资款的支付义务。</p><p>据悉，投资基金依据卢森堡大公国法律组建，专注于在世界范围内投资生命科学领域(特别是生物医药及医疗器械行业)的初创企业。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1211561.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1211561.html","article_id":"2483334901","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483334901","pubTimestamp":1731661716,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，药明康德 公告，2024年11月15日，公司全资子企业WuXi PharmaTech Healthcare Fund I L.P.与 Sofinnova Capital XI GP S.à r.l.签署 Subscription Agreement，约定由 WuXi Fund I 认缴 Sofinnova Capital XI SCSp SICAV-RAIF1000万欧元的投资基金份额，约占已募集投资基金份额的4.40% 。截至本公告日，WuXi Fund I尚未支付投资款，后续WuXi Fund I将以自有资金根据认购协议的要求履行投资款的支付义务。据悉，投资基金依据卢森堡大公国法律组建，专注于在世界范围内投资生命科学领域的初创企业。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","BK1141":"生命科学工具和服务","LU0052750758.USD":"富兰克林中国基金A Acc","BK1576":"医药外包概念","LU1997245177.USD":"安联神洲A股基金","02359":"药明康德","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1583":"高瓴概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0216":"研究试验","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"WuXi AppTec (603259. SH) wholly-owned subsidiary plans to subscribe for 10 million euros in investment fund shares","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1},"content_text":"智通财经APP讯，药明康德(603259.SH)公告，2024年11月15日，公司全资子企业WuXi PharmaTech Healthcare Fund I L.P.(简称“WuXi Fund I”)与 Sofinnova Capital XI GP S.à r.l.(简称“普通合伙人”)签署 Subscription Agreement(简称“认购协议”)，约定由 WuXi Fund I 认缴 Sofinnova Capital XI SCSp SICAV-RAIF(简称“投资基金”)1000万欧元的投资基金份额(简称“本次投资”)，约占已募集投资基金份额的4.40% (WuXi Fund I 所持投资基金份额比例将随投资基金后续募集金额增加而进一步稀释)。截至本公告日，WuXi Fund I尚未支付投资款，后续WuXi Fund I将以自有资金根据认购协议的要求履行投资款的支付义务。据悉，投资基金依据卢森堡大公国法律组建，专注于在世界范围内投资生命科学领域(特别是生物医药及医疗器械行业)的初创企业。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483334901"}